All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2019-06-28T08:58:44.000Z

Quizartinib rejected by FDA for FLT3-ITD AML

Jun 28, 2019
Share:

Bookmark this article

The FDA has decided not to grant approval to quizartinib for the treatment of patients with FLT3-internal tandem duplication-positive relapsed/refractory (R/R) acute myeloid leukemia, as results of a trial failed to show that the benefits of the treatment outweigh the risks.

At an Oncolytic Drug Advisory Committee (ODAC) meeting in May, panelists concluded in a 3-8 vote, that results of the study failed to show the benefits of quizartinib outweigh the risks for this subgroup of patients.

The panel questioned the lack of robust data, and the large proportion of randomly assigned, untreated patients. The committee also expressed concern over the risk and the modest survival results.

Quizartinib is a small molecule FMS-like tyrosine kinase-3-internal tandem duplication inhibitor that was submitted for approval based on the findings from the phase III QuANTUM-R study. Results from the study showed quizartinib reduced the risk of death by 24% compared with chemotherapy in patients with FLT3-ITD-positive R/R after first-line treatment with or without hematopoietic stem cell transplantation (HSCT).

Prior to the meeting, the FDA conducted its own efficacy analysis and found that the median overall survival (OS) was 26.9 weeks with quizartinib compared with 20.4 weeks with chemotherapy.

In the briefing document, the FDA explained how concerns were raised about the generalizability and credibility of the data.

The FDA is scheduled to make a final decision by the 25th August 2019.

  1. FDA Briefing Document Oncologic Drugs Advisory Committee (ODAC) Meeting May 14, 2019 NDA 212166 Quizartinib Applicant: Daiichi-Sankyo, Inc. Accessed Jun 28, 2019.https://www.fda.gov/media/124896/download.

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
14 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox